Gelonghui, April 19丨Warner Pharmaceuticals (688799.SH) announced that in order to keep up with the trend and trend of macromolecular innovative drugs becoming mainstream drug use around the world, use the investment experience and resources of professional investment institutions to explore investment opportunities in innovative application fields related to the pharmaceutical industry, strengthen the company's capabilities in macromolecular drug research and development, and actively use external talents and capital to complete the company's new drug R&D transformation and product upgrade strategy with efficiency and low risk. The company now plans to work as a limited partner, Beijing Qushan Investment Management Co., Ltd., Hunan Jinyang Investment Group The company and other partners signed a “partnership agreement” to jointly fund the establishment of a private equity fund, Hunan Queshan Huazi Industrial Investment Partnership (limited partnership).
Qeshan Huazi will focus on disease fields in China with high incidence rates and a large number of unsolved clinical problems, as well as investments in the field of innovative macromolecular drugs and devices, venture capital in unlisted companies in these fields through equity participation investments, or launch R&D project companies after thorough research. The company plans to use its own funds to pledge no more than RMB 10.00 million, accounting for 39.60% of the total pledged capital of the fund. The details are subject to the final signed “Partnership Agreement”.
The investment direction of the fund focuses on the medical and health sector in China. It invests in unlisted companies in the medical and health sector through venture capital or initiating the establishment of project R&D companies, which is relevant to the company's main business.